trending Market Intelligence /marketintelligence/en/news-insights/trending/CGGQ0Ymytzl6X1usc5WV_Q2 content esgSubNav
In This List

Celyad to pay $25M in cash, shares for greater share in oncology assets

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Celyad to pay $25M in cash, shares for greater share in oncology assets

Celyad SA said it will pay $12.5 million in cash and issue $12.5 million worth of its shares for a greater share of the future revenues generated by certain CAR-T cell therapies for the treatment of cancer.

Celyad had obtained access to the assets after the acquisition of OnCyte LLC from privately held Celdara Medical LLC in 2015. The assets were developed using technology licensed from the Dartmouth College.

Celyad will make the payment to Celdara Medical LLC and Dartmouth College. The development reflects increased confidence in the future potential of the assets, including CYAD-01.

Celyad said it will use the money received from Novartis AG to partially cover the cash portion of the agreement.